Another Phase 3 Trial Failure to Develop an Alzheimer’s Drug Shows Why Virgin Coconut Oil is Needed to Prevent Dementia by Brian Shilhavy, Editor, Health Impact News
After more than a decade of failed drug trials and $billions lost in research to try and bring an Alzheimer’s drug to market, maybe the pharmaceutical industry is finally ready to admit that they don’t really understand what causes Alzheimer’s disease.
It was announced earlier this week that Roche had failed for the second time to develop a successful Alzheimer’s drug.
Roche’s ‘high risk’ failure has industry circling the wagons on future of Alzheimer’s research
Another failure of an amyloid medicine for Alzheimer’s disease has companies, analysts and patient advocacy groups circling the wagons to once again defend the theory and the future of research into the devastating neurological disorder.
The theory that reducing or preventing amyloid plaques in the brain can slow cognitive decline has time and time again failed in the clinic…
Roche has added a second failure in Alzheimer’s to its tab this year, this time for gantenerumab, which did not improve the rate of cognitive and functional decline in two phase 3 clinical trials from the Graduate program. This follows the June disclosure that crenezumab had failed in a study of pre-symptomatic Alzheimer’s patients.
Roche CEO Severin Schwan called gantenerumab “a high-risk project” when reporting second-quarter earnings in July, and suggested that the company “plan for a situation where it doesn’t come through.”
GlobalData Senior Neurology Analyst Pippa Salter called the gantenerumab failure surprising, particularly that the med also did not seem to clear amyloid plaques as much as expected. She doesn’t see a path forward for the therapy.
“Its failure will be a significant blow to Roche, which had gambled on continued development of the product despite a previous phase 3 failure in 2014,” Salter said in a Tuesday note. (Full article.)
I have been reporting on the failure of Big Pharma to produce an Alzheimer’s drug for over a decade now, along with publishing numerous testimonies of how many people have reversed the effects of Alzheimer’s and dementia by using Virgin Coconut Oil in their diet, especially if it is part of an overall ketogenic diet which emphasizes healthy high fats, moderate levels of protein, and small amounts of carbohydrates.
Are Pharmaceutical Drugs One of the Causes of Alzheimer’s Disease?
In 2011, Dr. Stephanie Seneff published research looking at the effects of a low-fat diet and statin drugs in relation to Alzheimer’s Disease. This research noticed a strong correlation between insulin resistance in the brain and early Alzheimer’s Disease, suggesting that Alzheimer’s might be considered a neuroendocrine disorder of the brain or so-called “type 3 diabetes”.
But the study’s main conclusions regarding the early causes of Alzheimer’s Disease centered around the transport of cholesterol from the blood stream to the brain. The research stated that there is mounting evidence which suggests that a defect in cholesterol metabolism in the brain may play an important role in Alzheimer’s Disease. A nice summary of the brain’s dependency on cholesterol is given: